“Olanzapine Versus Typical Neuroleptics for Schizophrenia: Evaluation of Social and Economic Costs”. 2006. Farmeconomia. Health Economics and Therapeutic Pathways 7 (2): 119-24. https://doi.org/10.7175/fe.v7i2.681.